Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells
Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells
Ling YANG1, Rui ZHU2, Qingjing ZHU3, Dan DAN1, Jin YE1(), Keshu XU1, Xiaohua HOU1
1. Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430022, China; 2. Department of Traditional Chinese Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430022, China; 3. Department of Integrated Traditional Chinese Medicine and Western Medicine, Wuhan Municipal Hospital of Infectious Diseases, Wuhan 430022, China
This study aims to investigate the influence of β-elemene on the secretion of angiotensin II (ANG II) and the expression of angiotensin receptor type 1 (AT1R) in hepatic stellate cells (HSCs). In vitro, HSC-T6 were cultured for 24 hours and then treated with different doses of β-elemene (2.5, 5 and 10 mg/L). A control group was also set up. The secretion of ANG II in the supernatant was detected by radioimmunoassay. The mRNA expression of AT1R at 4, 12 and 24 h after treatment was detected by reverse transcription-polymerase chain reaction (RT-PCR), respectively. The protein expression of AT1R was detected by western blot. At the 4th h, the ANG II secretion in the supernatant was significantly inhibited by 10 mg/L β-elemene compared with the control group (P<0.05), while 5.0 mg/L and 2.5 mg/L β-elemene had no inhibitory effect on the secretion of ANG II (P>0.05). At the time point of the 12th h, the secretion of ANG II in the supernatant treated with 10 mg/L and 5.0 mg/L β-elemene was significantly lower than the control (P<0.01, P<0.05). Following the treatment with 5.0 mg/L and 2.5 mg/L β-elemene for 24 h, significant inhibition of ANG II secretion was observed (P<0.05), but 10 mg/L β-elemene had no such effect. β-elemene significantly reduced the amount of AT1R mRNA in HSCs after the treatment for 4, 12, and 24 h in a dose-dependent manner. The expression of AT1R protein also decreased after the treatment with β-elemene for 24 h. β-elemene can inhibit the secretion of ANG II and the gene and protein expression of AT1R, which may be the mechanism by which β-elemene prevents the progress of hepatic fibrosis.
Corresponding Author(s):
YE Jin,Email:yejin8689@sina.com
引用本文:
. Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells[J]. Frontiers of Medicine in China, 2009, 3(1): 36-40.
Ling YANG, Rui ZHU, Qingjing ZHU, Dan DAN, Jin YE, Keshu XU, Xiaohua HOU. Influence of β-elemene on the secretion of angiotensin II and expression of AT1R in hepatic stellate cells. Front Med Chin, 2009, 3(1): 36-40.
Friedman S L. Mechanisms of hepatic fibrogenesis. Gastroenterology , 2008, 134(6): 1655-1669 doi: 10.1053/j.gastro.2008.03.003
2
Li X, Meng Y, Huang M L, Zhang X L, Zhang Z S. Angiotensin II stimulates platelet-derived growth factor-B expression in hepatic stellate cells by activating EGR-1. Nanfang Yike Daxue Xuebao , 2008, 28(6): 963-967 (in Chinese)
3
Liu J, Gong H, Zhang Z T, Wang Y. Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J (Engl) , 2008, 121(2): 161-165
4
Liu C, Guo G, Hu Z Y. Effect of zedoary rhizome on the renal interstitial fibrosis in rats induced unilateral ureteral obstruction. Shanghai Zhongyiyao Zazhi , 2006, 40(12): 71-73 (in Chinese)
5
Xi Z T, Dan C M, Jiang W L, Luan X Y, Li K K. The study on common burreed tuber and zedoary rhizome resisting hepatic fibrosis induced autoimmunity in rats. Zhongguo Zhongyao Zazhi , 2002, 27(12): 929-932 (in Chinese)
6
Yang L, Qian W, Hou X H. Effect of the extract from Zedoray rhizome on ANG II and AT1R of rat liver fibrosis. Zhonghua Ganzangbing Zazhi , 2006, 14(4): 303-305 (in Chinese)
7
Yang L, Qian W, Hou X H. Effect of β-elemene on the cycle and apoptosis of hepatic stellate cells. Zhonghua Xiaohua Zazhi , 2006, 28(8): 555-556 (in Chinese)
8
Bataller R, Ginès P, Nicolás J M, G?rbig M N, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology , 2000, 118(6): 1149-1156 doi: 10.1016/S0016-5085(00)70368-4
9
Bataller R, Brenner D A. Liver fibrosis. J Clin Invest , 2005, 115(2): 209-218
10
Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev , 2006, 86(3): 747-803 doi: 10.1152/physrev.00036.2005
11
Bader M, Ganten D. Update on tissue rennin-angiotensin systems. J Mol Med , 2008, 86(6): 615-621 doi: 10.1007/s00109-008-0336-0
12
Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Tsujimoto T, Uemura M, Fukui H. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem , 2007, 14(26): 2749-2754 doi: 10.2174/092986707782360169
13
Kobori H, Nangaku M, Navar L G, Nishiyama A. The intrarenal rennin-Angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev , 2007, 59(3): 251-287 doi: 10.1124/pr.59.3.3
14
Wei H, Lu H, Li D, Zhan Y, Wang Z, Huang X. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4. World J Gastroenterol , 2000, 6(4): 540-545
15
Jonsson J R, Clouston A D, Ando Y, Kelemen L I, Horn M J, Adamson M D, Purdie D M, Powell E E. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology , 2001, 121(1): 148-155 doi: 10.1053/gast.2001.25480
16
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology , 2001, 34(4 Pt 1): 745-750
17
González-Abraldes J, Albillos A, Ba?ares R, Del Arbol L R, Moitinho E, Rodríguez C, González M, Escorsell A, García-Pagán J C, Bosch J. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology , 2001, 121(2): 382-388 doi: 10.1053/gast.2001.26288
